Nutriband Inc. Announces $8.4M Private Placement
- Nutriband is targeting a 505(b)(2) NDA to the FDA for marketing approval of AVERSA™ Fentanyl in Q1 2025 ORLANDO, FL / ACCESSWIRE / April 19, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of abuse deterrent pharmaceutical products announced that it has entered into definitive securities purchase agreements for the purchase and sale of an aggregate of 2,100,000 shares of common stock (the "Shares"), at a purchase price of $4 per share of common stock; for each Share of common stock purchased the investor receives a five-year warrant to purchase two shares of common stock. The exercise price of the Warrants is $6.43 per share.
- 04/19/2024
|
Nutriband Announces Data Supporting Need for Safer Abuse-Deterrent Transdermal Patches Presented at 2024 American Academy of Pain Medicine Annual Meeting
- Data highlights the incidence of abuse and accidental pediatric exposure of transdermal patches containing opioid and stimulant drugs Nutriband's AVERSA™ technology addresses the unmet need for safer abuse-deterrent transdermal patches ORLANDO, FL / ACCESSWIRE / March 25, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that data on the incidence of transdermal patch abuse and accidental pediatric exposure was presented at the 2024 American Academy of Pain Medicine (AAPM) Annual Meeting on March 8, 2024. The American Academy of Pain Medicine (AAPM) is dedicated to advancing multidisciplinary pain care, education, advocacy, and research.
- 03/25/2024
|
Prescription Transdermal Patch Abuse and Accidental Pediatric Exposure Remains a Serious Problem in the United States - Surveillance Data to Be Presented at 2024 American Academy of Pain Medicine Annual Meeting
- ORLANDO, FL / ACCESSWIRE / March 4, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that data on the incidence of transdermal patch abuse and accidental pediatric exposure will be presented at the 2024 American Academy of Pain Medicine (AAPM) Annual Meeting to be held in Scottsdale, Arizona March 7-10, 2024. The company engaged Rocky Mountain Poison & Drug Safety (RMPDS), a division of Denver Health and Hospital Authority, Denver, Colorado to determine the incidence of abuse and accidental pediatric exposure of transdermal patches containing drugs of abuse in the United States.
- 03/04/2024
|
Nutriband Inc. to Present at The Microcap Conference Atlantic City January 30th through February 1st
- Nutriband Inc. to Present at The Microcap Conference Atlantic City January 30th through February 1st. ORLANDO, FL / ACCESSWIRE / January 29, 2024 / Nutriband Inc. (Nasdaq:NTRB)(Nasdaq:NTRBW) today announced that it will be presenting at the Dealflow Events MicroCap Conference taking place January 30th through February 1 in Caesars Atlantic City.
- 01/29/2024
|
Nutriband CEO Publishes Letter to Shareholders
- ORLANDO, FL / ACCESSWIRE / January 26, 2024 / Nutriband Inc. ("Company") (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced that CEO Gareth Sheridan has published a letter to shareholders providing insights on achievements and targets through 2023 and the potential outlook for 2024. The full text of the letter is below.
- 01/26/2024
|
Nutriband Inc. Expands its AI Kinesiology Tape Portfolio with the Launch of AI Tape Heating and Cooling
- ORLANDO, FL / ACCESSWIRE / November 28, 2023 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced the launch of its new Heating and Cooling Kinesiology Tape as part of its Active Intelligence (AI Tape) Brand portfolio. AI Tape Heating and Cooling provides all of the stretch, support, and benefits of traditional kinesiology tape, plus pain-relieving ingredients that provide both heating and cooling sensation for the temporary relief of minor aches and pains of muscles and joints.
- 11/28/2023
|
Nutriband Inc. Signs Supplier Agreement With KT Tape, the World Leader in Kinesiology Tape
- ORLANDO, FL / ACCESSWIRE / November 8, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that it has signed a supplier agreement with market leading kinesiology tape company, KT Tape. Nutriband Inc.'s wholly owned contract manufacturing subsidiary, Active Intelligence, will act as manufacturer for a new line of specialized KT tape.
- 11/08/2023
|
Nutriband's Aversa(TM) Buprenoprhine May Reach Peak Annual Sales of $70-130 Million Based on Market Assessment by Leading Healthcare Consulting Firm
- ORLANDO, FL / ACCESSWIRE / October 11, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of transdermal pharmaceutical products, today announced it has completed the market assessment and commercialization strategy for AVERSA™ Buprenorphine, an abuse deterrent buprenorphine transdermal system. The company engaged leading healthcare consulting company Health Advances to assess the market opportunity and commercial strategy for Aversa™ Buprenorphine, which has the potential to be the world's first buprenorphine transdermal system with abuse deterrent properties.
- 10/11/2023
|
Nutriband Announces Issuance of U.S. Patent for Transdermal Abuse Deterrent Technology
- Patent issuance expands U.S. patent portfolio for AVERSA™ transdermal abuse deterrent technology ORLANDO, FL / ACCESSWIRE / September 20, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that the United States Patent and Trademark Office (USPTO) has granted US Patent No. 11,759,431 for Nutriband's proprietary AVERSA™ abuse deterrent technology utilizing taste aversion to address the primary routes of abuse of opioid based transdermal patches.
- 09/20/2023
|
Nutriband Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update
- Second quarter 2023 revenues increased 48% compared to second quarter 2022 ORLANDO, FL / ACCESSWIRE / September 11, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced financial and operational results for the second quarter ended July 31, 2023. Key Highlights: Generated quarterly revenue of $655,928, up 48% over Q2 2022 Revenue for six-months ended July 31, 2023, was $1,132,869, up 21% year-over-year Increased Existing Credit Line to $5 Million supporting the continued development of AVERSA Launched AI Tape Brand and announced Donovan McNabb as AI Tape Brand Ambassador Stockholders' equity of $6.9 million as of July 31, 2023 "We are encouraged by the continued revenue growth from Nutriband's subsidiaries, especially our Pocono Pharmaceuticals segment.
- 09/11/2023
|
Nutriband Inc. Announces Donovan McNabb as AI Tape Brand Ambassador
- AI Tape has potential to tap into the $236 million Elastic Therapeutic Tape market ORLANDO, FL / ACCESSWIRE / August 30, 2023 / Nutriband Inc. (the "Company") (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announces that it has engaged former 6-time Pro-Bowl NFL quarterback, Donovan McNabb as a brand ambassador for its Active Intelligence Tape ("AI Tape") consumer sports recovery tape brand. Mr. McNabb played in the NFL for 13 seasons, primarily with the Philadelphia Eagles.
- 08/30/2023
|
Nutriband Inc. Launches AI Tape Brand Direct-to Consumer Offerings
- ORLANDO, FL / ACCESSWIRE / July 27, 2023 / Nutriband Inc. (the "Company") (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced the launch of its consumer sports recovery tape brand, Active Intelligence AI Tape ("AI Tape"), with products now available for purchase on Amazon and Activeintell.com . AI Tape is designed to combine many of the traditional benefits of kinesiology tape with the addition of soothing and therapeutic ingredients held in suspension with a proprietary adhesive mix.
- 07/27/2023
|
Nutriband Increases Existing Credit Line to $5 Million USD for the Development of its AVERSA(TM) Platform Towards FDA Submission
- Company targeting FDA submission in the first half of 2024 AVERSA ™ Fentanyl is the flagship product of the Company's AVERSA™ Platform ORLANDO, FL / ACCESSWIRE / July 14, 2023 / Nutriband Inc. ("Company") (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that it has expanded its existing Credit Line facility to $5 Million USD to fund the continued development and regulatory submission process for the Company's patented lead product platform, AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal system. The Company is targeting FDA submission for AVERSA™ Fentanyl in the first half of 2024.
- 07/14/2023
|
Nutriband Inc. to Present at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023
- ORLANDO, FL / ACCESSWIRE / April 19, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a pioneer in the development of innovative transdermal solutions, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023 at 08:30 AM (Local Time -PST). Company CEO, Gareth Sheridan will be hosting the presentation and answering questions at the conclusion.
- 04/19/2023
|
Nutriband Subsidiary, 4P Therapeutics LLC, Conducts Phase 1b Clinical Study for Sorrento Therapeutics, Inc. on Lymphatic Etanercept Delivery in Rheumatoid Arthritis Patients With Results To Be Presented at the 2022 American College of Rheumatology Confere
- ORLANDO, FL / ACCESSWIRE / October 26, 2022 / Nutriband Inc. (the "Company") (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced that its subsidiary, 4P Therapeutics LLC ("4P Therapeutics"), has conducted a Phase 1b clinical study for Sorrento Therapeutics, Inc. ("Sorrento") (NASDAQ:SRNE) with results to be presented at the American College of Rheumatology (ACR) Convergence 2022 Conference on November 13, 2022 as a poster abstract entitled "Lymphatic Delivery of Etanercept Achieves Significant Improvements in Rheumatoid Arthritis Disease Measures at 50% of the Standard Dose for Patients with an Inadequate Response to Subcutaneous Injections." "We are excited about these proof of concept clinical results and the development of Sorrento's Sofusa lymphatic delivery platform for treatment of autoimmune diseases such as rheumatoid arthritis to provide hope for those patients who do not respond adequately to conventional biologic injections," said Alan Smith, Ph.D.
- 10/26/2022
|
Nutriband Inc. to Present at the Emerging Growth Conference on May 25
- Nutriband Inc. Invites Individual and Institutional Investors As Well as Advisors and Analysts, To Attend Its Real-Time, Interactive Presentation at the Emerging Growth Conference ORLANDO, FL / ACCESSWIRE / May 20, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), is pleased to announce that it has been invited to present at the Emerging Growth Conference on May 25, 2022. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's CEO, Gareth Sheridan, in real time.
- 05/20/2022
|
Nutriband Stock (NTRB): Why The Price Surged Today
- The stock price of Nutriband Inc (NASDAQ: NTRB) increased by over 40% during intraday trading today. This is why it happened.
- 01/11/2022
|
Nutriband Stock (NTRB): Why The Price Skyrocketed Today
- The stock price of Nutriband Inc (NASDAQ: NTRB) surged over 180% today. This is why it happened.
- 12/31/2021
|
Nutriband stock more than doubles in very active trading after a full patent was issued in South Korea
- Shares of Nutriband Inc. NTRB, +117.01% rocketed 126.6% in very active trading Friday morning, after the developer of a fentanyl abuse deterrent patch said it was issued a full patent in South Korea for its lead technology Aversa. Volume spiked to 31.8 million shares, compared with the full-day average of roughly 55,300 shares, and enough to make the stock the most actively traded on major U.S. exchanges.
- 12/31/2021
|
Hot Penny Stocks To Buy Before 2022? 3 Premarket Stocks To Watch
- Premarket penny stocks to watch on December 31, 2021. The post Hot Penny Stocks To Buy Before 2022?
- 12/31/2021
|
Why Nutriband Shares Are Soaring Today
- Nutriband Inc (NASDAQ: NTRB) is soaring Friday morning after the company announced the Korean Intellectual Property Office fully issued its patent titled "Abuse and Misuse Deterrent Transdermal System" which is related to the company's lead technology AVERSA. AVERSA is 4p Therapeutics' abuse deterrent transdermal system, which uses taste aversion to address the primary routes of abuse for opioid based transdermal patches.
- 12/31/2021
|
Hot Penny Stocks for Tuesday: Today's 10 Biggest Movers
- Penny stocks are on the move Tuesday and we're taking a look at what's hot among traders of the volatile investments today. The post Hot Penny Stocks for Tuesday: Today's 10 Biggest Movers appeared first on InvestorPlace.
- 10/12/2021
|
NTRB Stock: Why It Substantially Increased Today
- The stock price of Nutriband Inc. (NASDAQ:NTRB) increased by over 35% during intraday trading today. This is why it happened.
- 10/12/2021
|
NTRB Stock: 11 Things for Nutriband Investors to Know About the Covid-19 Antibody Indicator Patch
- Nutriband (NTRB) stock is taking off on Tuesday thanks to news that it will be producing Covid-19 antibody check patches. The post NTRB Stock: 11 Things for Nutriband Investors to Know About the Covid-19 Antibody Indicator Patch appeared first on InvestorPlace.
- 10/12/2021
|
NTRB Stock: Why It Substantially Increased Today
- The stock price of Nutriband Inc (NASDAQ: NTRB) increased by over 23% today. This is why it happened.
- 10/07/2021
|
Nutriband Inc. Prices $6.6 million Public Offering and Announces Uplisting to the NASDAQ Capital Market
- ORLANDO, FL / ACCESSWIRE / October 1, 2021 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a company engaged in the development of pharmaceutical products focused on preventing opioid abuse, contract research and development services and the contract manufacturing of topical and transdermal products, today announced that its common stock and warrants will begin trading on the Nasdaq Capital Market effective October 1, 2021. Nutriband also announced the pricing of an underwritten public offering of 1,056,000 units of securities at a public offering price of $6.25 per unit for total gross proceeds of $6.6 million, before deducting underwriting discounts and commissions and other estimated offering expenses.
- 10/01/2021
|
Strength Seen in Nutriband Inc. (NTRB): Can Its 22% Jump Turn into More Strength?
- Nutriband Inc. (NTRB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- 08/23/2021
|
New Strong Sell Stocks for July 14th
- COHU, NTRB, HELE, CNR, and SELB have been added to the Zacks Rank #5 (Strong Sell) List on July 14, 2021
- 07/14/2021
|
New Strong Sell Stocks for July 12th
- ACCD, CMTL, HEXO, NTRB, and GP have been added to the Zacks Rank #5 (Strong Sell) List on July 12, 2021
- 07/12/2021
|
